CAMURUS AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 550.5 SEK | -1.70% |
|
-2.91% | +2.32% |
| 01:18pm | Camurus' Rare Growth Disorder Drug Accepted for Review in EU | MT |
| May. 08 | Transcript : Camurus AB, Q1 2024 Earnings Call, May 08, 2024 |
Presentation Operator MessageOperator (Operator)Welcome to Camurus Q1 Report 2024. [Operator I...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Camurus AB is a Sweden-based research and development based pharmaceutical and biotechnology company with a focus on the development and marketing of specialty medicines, providing patients suffering from severe and chronic disease, such as opioid dependence, pain, cancer, and endocrine diseases. The Company has a diversified research portfolio, which includes products in clinical trials. The Companyâs products are based on FluidCrystal formulation technology. FluidCrystal is Company's patent-protected technology platform. Camurus AB is the parent company of the Group, which comprises of legal entities, namely: Camurus Inc, Cubosome Inc, Development AB, Camurus GmbH, Camurus Ltd, Camurus Oy, Camurus AS, Camurus SAS, Camurus Pty Ltd, Camurus S.L, Camurus ApS, Camurus BV and Camurus Austria GmbH.
Sector
Pharmaceuticals
Calendar
2024-05-22
- SEB Small- & Midcap Seminar
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
560
SEK
Average target price
593.2
SEK
Spread / Average Target
+5.92%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +2.32% | 3.01B | |
| +38.69% | 723B | |
| +34.28% | 595B | |
| -4.49% | 369B | |
| +20.24% | 332B | |
| +2.12% | 282B | |
| +17.02% | 244B | |
| +9.31% | 208B | |
| -5.07% | 205B | |
| -0.35% | 168B |
- Stock Market
- Equities
- CAMX Stock
- News Camurus AB
- Transcript : Camurus AB, Q1 2024 Earnings Call, May 08, 2024
